John Giammona Appointed President, Chief Commercial Officer at KUR International

September 18, 2024 03:02 AM AEST | By EIN Presswire
 John Giammona Appointed President, Chief Commercial Officer at KUR International
Image source: EIN Presswire
DALLAS, TEXAS, UNITED STATES, September 17, 2024 /EINPresswire.com/ -- KUR International, a global healthcare conglomerate dedicated to furthering science, research, and patient well-being, today announced John Giammona, PhD, has been appointed President and Chief Commercial Officer. Mr. Giammona will lead the strategic and operational direction of the clinical research, biobank, and diagnostics services groups. This addition to KUR International’s executive leadership team marks a significant milestone in the company's ambitious expansion and commercial endeavors. KUR International’s founder and Chief Executive Officer, Adam Maciak, previously managed these duties and will continue to spearhead the execution of the company’s expansion plans.

Mr. Giammona brings a wealth of industry experience and achievement to the company, including a proven track record of driving growth and forging strategic business partnerships in the clinical research and biopharma sectors. Most recently, he helped drive pharma partnerships at Tasso, Inc., supporting decentralized clinical trial technologies and services. Previous roles include Vice President and Head of Medical Affairs at both Shield Therapeutics and Acasti Pharma, Chief Business Development Officer at the Alliance for Multispecialty Research, and Global Head of Strategic Operations (Early Clinical Development Division) at PPD. Mr. Giammona earned a Doctorate in Pharmacology and Toxicology from the University of Texas at Austin’s College of Pharmacy and has a Master of Science Degree in Environmental Science and Engineering from the Colorado School of Mines. He began his diverse career in the clinical research industry over 20 years ago with Radiant Research, Inc., one of the first wholly-owned site networks.

“We have witnessed unprecedented innovation and technological advancements, especially following the pandemic. I am excited to be part of KUR as we expand our role in the drug development and diagnostics industries through continued service delivery innovation and operational excellence," said Mr. Giammona. “Patient recruitment remains a big challenge in clinical research. KUR’s community-based clinical research model puts the company in a position to expand patient access and diversity here in the U.S."

“John is a visionary leader with over two decades of experience in asset development across clinical research organizations (CROs), clinical research sites and networks, medical device companies, and biopharmaceutical corporations. His strategic mindset, as well as his positive leadership style, have already benefited the organization. John has rapidly added strong talent to the team from the clinical research industry. Additionally, he is implementing dynamic initiatives that position KUR to grow by serving our teams, sponsors, CROs, and clinical research volunteers,” shared Mr. Maciak. “From forging new biopharma and diagnostics partnerships to expanding KUR’s clinical research site network footprint, his role is crucial in driving company growth and success.”

About KUR International
KUR International was founded in 2014 as a global healthcare company dedicated to furthering science, research, and patient well-being. The company strives to help advance clinical research by delivering a seamless and positive clinical experience for clinical research volunteers. KUR International is supported by Atlas Essentials, the management organization for all KUR entities. KUR International includes KUR Research, Urgent Care Center Trials (UCCT), Vexillum (a geographically diverse infectious disease biobanking business unit) and KUR Diagnostics.

For more information about KUR International, visit www.kurintl.com. You can also contact John Giammona, PhD, or one of KUR’s business development directors at [email protected].

Jaime Hudson
KUR International
email us here
Visit us on social media:
Facebook
LinkedIn
Instagram
YouTube
TikTok

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.